ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Imatinib mesylate

Imatinib mesylate

Imatinib mesylate Suppliers list
Company Name: Jinan Jianfeng Chemical Co., Ltd
Tel: 15562555968
Email: info@pharmachemm.com
Products Intro: Product Name:Imatinib Mesylate
CAS:220127-57-1
Purity:99% Package:5KG;1KG
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Email: sales@frappschem.com
Products Intro: Product Name:Imatinib mesylate
CAS:220127-57-1
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:Imatinib Mesylate
CAS:220127-57-1
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Imatinib mesylate
CAS:220127-57-1
Purity:99% Package:3300/KG
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Imatinib mesylate
CAS:220127-57-1
Purity:99% Package:100g,500g,1KG,10KG,100KG

Lastest Price from Imatinib mesylate manufacturers

  • Imatinib mesylate
  • US $7.00 / kg
  • 2019-04-01
  • CAS:220127-57-1
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
  • Imatinib mesylate
  • US $1.00 / KG
  • 2019-04-01
  • CAS:220127-57-1
  • Min. Order: 1G
  • Purity: 98%
  • Supply Ability: 100KG
  • Imatinib mesylate
  • US $100.00 / KG
  • 2019-04-01
  • CAS:220127-57-1
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: Customized
Imatinib mesylate Basic information
a small-molecule inhibitor
Product Name:Imatinib mesylate
Synonyms:Imatinib for system suitability;Imatinib mesylate / 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide;Gleevec (Imatinib);IMatinib Mesylate(STI-571);Imantinib mesylate;4-[(4-Methyl-1-piperazinyl)Methyl]-N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]benzaMide Methanesulfonate;GLIVEC
CAS:220127-57-1
MF:C30H35N7O4S
MW:589.71
EINECS:606-892-3
Product Categories:Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors;Aromatics;Heterocycles;API;Glivec, CGP-57148B, STI-571;Active Pharmaceutical Ingredients;Antineoplastic;Anti-cancer&immunity;Inhibitors;Anticancer
Mol File:220127-57-1.mol
Imatinib mesylate Structure
Imatinib mesylate Chemical Properties
Melting point 214-224°C
storage temp. -20°C Freezer
solubility H2O: soluble10mg/mL, clear
form White solid
color white to beige
InChIKeyYLMAHDNUQAMNNX-UHFFFAOYSA-N
CAS DataBase Reference220127-57-1(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
RTECS CV5520550
Hazardous Substances Data220127-57-1(Hazardous Substances Data)
MSDS Information
Imatinib mesylate Usage And Synthesis
a small-molecule inhibitorImatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.
Chemical PropertiesOff-White Solid
UsesA tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
UsesImatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
UsesImatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
Usesechinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
DefinitionChEBI: A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.
General DescriptionImatinib is available in 100- and 400-mg capsules for oraladministration and is indicated for the treatment of CML,gastrointestinal stromal tumors (GIST) that express Kit andacute lymphoplastic leukemia that is positive for thePhiladelphia chromosome.
Bioavailability of the agent is nearly 100% by the oralroute. The agent is highly protein bound and metabolized tothe N-desmethyl derivative by CYP3A4-mediated removalof the piperazinyl methyl group. The resulting metabolite issimilar to the parent in activity. Elimination occurs primarilyin the feces, and the terminal half-life is 18 hours forthe parent and 40 hours of the N-desmethyl metabolite.Resistant forms of the TK are known, which have alteredamino acids that prevent binding. In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. Severe side effects include ascites,neutropenia, thrombocytopenia, skin rash, andpulmonary edema. Less serious side effects include nausea/vomiting, heartburn, and headache but overall, the agentis better tolerated than most other medications used in treatingthe disease.
Imatinib mesylate Preparation Products And Raw materials
Tag:Imatinib mesylate(220127-57-1) Related Product Information
1,2,3-Triacetyl-5-deoxy-D-ribose Gemcitabine Gemcitabine hydrochloride Methylparaben Bensulfuron methyl Imatinib mesylate Kresoxim-methyl Methyl Methyl bromide 2-Aminopyridine Methyl acrylate Thiophanate-methyl 3-Aminopyridine Gatifloxacin mesylate Pazufloxacin mesilate Pefloxacin mesylate Methyl acetate Imatinib mesylate